Jaguar Health, Inc. (JAGX) - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Jaguar Health, Inc. on December 12, 2025. The filing discloses the entry into material definitive agreements and unregistered sales of equity securities involving the exchange of Series M Perpetual Preferred Stock for common stock and pre-funded warrants.
Key Financial Metrics
The filing does not provide standard financial metrics such as revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on capital structure transactions.
Material Changes and Transactions
The Company executed two privately negotiated exchange transactions with Iliad Research and Trading, L.P. ("Iliad") to retire Series M Preferred Stock:
- First Exchange Transaction (December 9, 2025):
- Retired 75 shares of Series M Preferred Stock.
- Issued 400,000 shares of Common Stock.
- Issued a pre-funded warrant to purchase 1,304,545 shares of Common Stock.
- Second Exchange Transaction (December 11, 2025):
- Retired 16 shares of Series M Preferred Stock.
- Issued 40,000 shares of Common Stock.
- Issued a pre-funded warrant to purchase 304,827 shares of Common Stock.
Warrant Terms: Both pre-funded warrants are immediately exercisable at $0.001 per share. Exercise is capped to ensure the holder's beneficial ownership does not exceed 9.99% of total outstanding shares.
Guidance, Risks, and Contingencies
The filing does not contain forward-looking guidance, management commentary on operations, or specific risk factors beyond the standard representations and warranties customary for such transactions. The securities were issued in reliance on the Section 3(a)(9) exemption from registration under the Securities Act of 1933.
Investor Verification Checklist
- Verify the total number of Series M Preferred Shares remaining outstanding after the retirement of 91 shares (75 + 16).
- Confirm the dilution impact of the 440,000 common shares issued and the potential issuance of 1,609,372 shares via pre-funded warrants.
- Review the full text of the Exchange Agreements (Exhibits 10.1 and 10.2) for covenants or restrictions not detailed in the summary.
- Check subsequent filings for the exercise status of the pre-funded warrants.